<SEC-DOCUMENT>0001193125-14-248029.txt : 20140627
<SEC-HEADER>0001193125-14-248029.hdr.sgml : 20140627
<ACCEPTANCE-DATETIME>20140625072833
ACCESSION NUMBER:		0001193125-14-248029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140625
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140625
DATE AS OF CHANGE:		20140625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORASURE TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001116463
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				364370966
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16537
		FILM NUMBER:		14938699

	BUSINESS ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
		BUSINESS PHONE:		5036416115

	MAIL ADDRESS:	
		STREET 1:		150 WEBSTER ST
		CITY:			BETHLEHEM
		STATE:			PA
		ZIP:			18015
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d747703d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;25, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>OraSure Technologies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-16537</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-4370966</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>220 East First Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bethlehem, Pennsylvania</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>18015-1360</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: 610-882-1820 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 &#150; Regulation FD Disclosure. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;25, 2014, OraSure Technologies, Inc. (the &#147;Company&#148;) issued a press release providing an update on the Company&#146;s substance abuse
testing business and updating its second quarter 2014 financial guidance. A copy of this press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item and attached Exhibit shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such
a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the
information contained in this Current Report or attached Exhibit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 &#150; Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June 25, 2014, providing an update on the Company&#146;s substance abuse testing business and updating its second quarter 2014 financial guidance.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Signatures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">O<SMALL>RA</SMALL>S<SMALL>URE</SMALL> T<SMALL>ECHNOLOGIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: June&nbsp;25, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><I>/s/ Jack E. Jerrett</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Jack E. Jerrett</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Senior Vice President, General Counsel and Secretary</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Index to Exhibits </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated June&nbsp;25, 2014, providing an update on the Company&#146;s substance abuse testing business and updating its second quarter 2014 financial guidance.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d747703dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g747703ex99_1pg001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ronald H. Spair</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Media Contact:</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Jennifer Moritz</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">610-882-1820</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Zer0 to 5ive for OraSure Technologies</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>Investorinfo@orasure.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">917-748-4006</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>www.orasure.com</U></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">jmoritz@0to5.com</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ORASURE PROVIDES UPDATE ON SUBSTANCE ABUSE TESTING BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Now Projects Net Profit for Second Quarter </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETHLEHEM, Pa. &#150; June&nbsp;25, 2014 &#150;</B> OraSure Technologies (NASDAQ: OSUR), a market leader in point of care diagnostics, announced today
continued progress under its agreement with Thermo Fisher Scientific (Thermo Fisher) to develop and supply homogenous fully-automated oral fluid drugs of abuse assays to be used with a new version of the Company&#146;s Intercept<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> oral fluid specimen collection device. The NIDA-5 panel of automated assays developed by Thermo Fisher and the new Intercept oral fluid specimen collection device are expected to launch in the
domestic criminal justice and forensics markets in the fourth quarter of 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this progress, OraSure has issued its final purchase order
for fully-automated assays previously developed under its now terminated collaboration with Roche Diagnostics. Under the Roche Diagnostics collaboration, which was terminated in November 2013, OraSure is entitled to receive $5.5 million as a result
of its submission of a final purchase order. Payment is expected to be received during the third quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the $5.5 million payment
expected from Roche Diagnostics, the Company is reaffirming its projected range of consolidated net revenues of $26.0 to $26.5 million and is now projecting consolidated net income of approximately $.01 to $.02 per share for the second quarter of
2014. The payment from Roche will be recorded as a reduction of the Company&#146;s operating expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The progress we have made on the development
of our new Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> collection device and the optimization of this device with the homogenous assays developed by Thermo Fisher, enables us to place our final purchase order with
Roche,&#148; said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. &#147;The anticipated launch of our new device with the Thermo Fisher assays later this year will be an important development for our substance
abuse testing business.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure and Thermo Fisher signed an agreement in November 2013 that will enable OraSure to provide its customers with
fully-automated oral fluid assays that can be used by laboratories on their existing clinical chemistry automated analyzers, allowing oral fluid samples to be processed with the same efficiency as current fully automated urine-based drug tests.
These assays will be used with OraSure&#146;s new Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> collector, </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which features a volume indicator that activates when a sufficient oral fluid sample has been collected. This new feature is expected to better serve the future needs of OraSure&#146;s drug
testing customers. Under its agreement with Thermo Fisher, OraSure will have the right to purchase and resell the assays in the U.S. and in certain foreign countries, subject to receipt of applicable regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure&#146;s current Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Oral Fluid Drug Testing System was the first FDA-cleared in-vitro
diagnostic laboratory-based oral fluid drug testing system, and is the only one that is FDA cleared for detection of nine commonly abused drugs, including marijuana, cocaine, opiates, PCP, amphetamines, methamphetamine, barbiturates, methadone and
benzodiazepines. It combines the ease, efficiency, and cost savings of oral fluid collection with increased sample integrity and the accuracy of laboratory-based drug tests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Intercept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Oral Fluid Drug Testing System is primarily being used in the workplace, drug
treatment and criminal justice drug testing markets. To learn more about OraSure&#146;s Substance Abuse Testing products, please visit <U>http://www.orasure.com/products-substance/products-substance-abuse.asp</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About OraSure Technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OraSure Technologies is a
leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the
detection of antibodies to HIV and HCV at the point of care and tests for detecting various drugs of abuse. The Company sells the OraQuick<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> In-Home HIV Test, the first and only rapid HIV test
approved by the U.S. Food and Drug Administration for sale to the consumer over-the-counter market in the U.S. In addition, the Company is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular
diagnostic applications. OraSure&#146;s portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions,
distributors, government agencies, physicians&#146; offices, and commercial and industrial entities. The Company&#146;s products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve
and protect their health. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on OraSure Technologies, please visit www.orasure.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OraSure Technologies Forward-Looking Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
press release contains certain forward-looking statements, including with respect to expected revenues, net income and product usage. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that
could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through our internal, direct sales force or third
parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new
indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectively resolve warning letters, audit observations and other findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with
strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or
minimum purchase requirements for the Company&#146;s products; impact of replacing distributors; inventory levels at distributors and other customers; ability of DNA Genotek to achieve its financial and strategic objectives and continue to increase
its revenues; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment and poor credit
conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products; market acceptance of oral fluid testing or other
products; changes in market acceptance of products based on product performance or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution
channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of the Company&#146;s products; history of losses and ability to achieve
sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of the Company&#146;s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty
and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and
manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of
capital; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and
ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in the Company&#146;s Securities and
Exchange Commission filings, including its registration statements, Annual Report on Form 10-K for the year ended December&nbsp;31, 2013, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to
provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to
update these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g747703ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g747703ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4P$W`P$1``(1`0,1`?_$`.,``0``!@,!`0``````
M```````%!@<("0H!`P0""P$!```'`0$```````````````(#!`4&!P@!"1``
M``8!`P(#`P8%#0D1`0```0(#!`4&!P`1"!(3(3$)(A0505%A(Q<*@:$R)!9Q
MD4)2,S0UE]<X2%@:L>)STT149#:(P>'Q8G*20U.3)2<WMRAXF!DZ$0`"`0,#
M`@,#!@<)#`@'```!`@,`$002!08A,4%1$V$B!W&1,B,4%8&AL4)2,Y1RTT2T
MU%46"!CPP6*"DK)#LR1TA'714S1D1387-^'QHG,UE3C_V@`,`P$``A$#$0`_
M`-OKU*^:\GP!XPR?(:)QLURL[C[M2ZB6I.[0M4$5B6V058G?C,H0-D4(9@"?
M4"?NP@H([=1?/6>?#CAD?/>3+QZ7).*K0R2>H$$A&@7MI+)W\]72L(^(/,&X
M/QQ]^3'&25E1-!<I?5?KJ"OXBUK>-:\7]JBOG]1B"_C[E?Y']=!_V7,+^?'_
M`&5?Y16@/[3F7_,H_:&_>*?VJ*^?U&(+^/R4_D@T_LNX0_\`''_95_E%/[3F
M5_,H_:&_>*#]ZBO@?T&(+\&>Y3^2#3^RYA>&^/\`LJ_RBG]IS*_F4?M#?O%/
M[5'?/ZC$%_'W*?R0:\']5W!/_CC_`+*O\HKT_P!9O+'?9!?_`'AOWBNPWWIS
M()$TEC\$X8B2_<[*IL\2P)K=D_;5[1QP]TJ=H_LFV$>D?`=>#^J_MY8J-\<L
M.X^S+TOVO_M%1-_68SE4.VQV0]CZ[V/R?4=>]=?]JBOG]1F!^?;[?)3?;^*#
M7O\`9=PKV^_'O_NJ_P`HJ`?UG,L_^"#]H;]XI_:HKY_48@OX^Y7^1_7O]ES"
M\=[?]E7^44_M.Y?\R#]H;]XI_:HKY_48@OX^Y3^1_3^RYA?SX_[*/W^G]IS*
M_F4?M#?O%<?VJ.^;?S&(/^/N5_D?T_LN87\^/?\`W5?Y13^TYE?S*/VAOWBM
MHKA]GQWRDXPX1Y#/JJC2'>7J##W5>I-Y<\\C`*2A51-')3*L=$*2)$.WX*BV
M0$V_Y(:YAY9L:\9Y)F[`DIF7$G:/65TEM/CINUODN?EKICB^]'D?'\3?#'Z7
MVJ$/HOJTW\+V%_EL*N2UCU7ZFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2L,OKR0?Z0^G_`#L;V^[U9;Q.
MOT_X&>6-OY#Y:V]\$,C[-SM);V/V6<?.M:[^*&(N;Q5H&%QZ\1^9JTG?LHW$
M/S8/U-AW_$778_WLWF:YQ/&XOT17/V3COX-@V^;IV_N%'7GWP?!C^.@XW%^B
M*F=_Q^DV55@KF1F#NO3LC+00/D$S]$;984K=R^@)'V1!N^/%/6SUOOL#ALL)
MB>*2H$IH^1(^5)A%BN2BJUCXHUP''LU`J?)AU[B]0_%%6!<@*#"Q(OY,+74^
MVQ!'F#T[&U6YOC&E(\8Z%F>'C@$];RG<L+7_`+*8;I.7T9'9%QO*N>DHB7XE
M'R<RQZC>?PY,OGMJTP<G>/DL^S3,;28L>1%\@8PRK^`B-O\`&)JNFXE!)LL.
M>B#5',\+_AM)&3\H9U]FD"HS?^-Z3#B;QER(BQ3(M8<B\DZL^7`@`=4(%_C1
M]%E5';J'H*^=@3?RV';Y=I.!R0ORK<MO)-DQ\1P/+4)@WY%^>IN5Q6$;!A3A
M>IFR5/\`E1D?WZE-WQJ3@N-\'DR1C@"1R3F6:J=6,HG[8UG%]2:O+6]0$Q1,
M"+ZRWQ@V$0\!.P.&_@.JI.2M-R-]M1OJ\;#5W_=S2$1_,D3G_&!\JD'B<,.S
M#*=/K)LDJO3\V-?>/X6D`_Q:IHCQ^E3U![=UF96T"WL#2JLW*Q3%^+V!=DI*
MNXV-]GZX\/$)E</#_DH%<-RF]I=,!N;<@098P@Q,YC+D?HH#I!/EJ;HOG9K?
M1-40XJAQSDZ0(@P4=.[$7L/.PZGRNH[FI<^R??Q]T#?Y/#Q_7Z=5'WP?TC4D
M\<A_1%/LG_T7?]0/[W3[W/Z1_'7G]'(OT1:OT#?3&C_A7I_\2XWIZ0988JR'
M1^UZ$UP\M<(_$>3U>=[K(?SLQS\YKJOA<`QN*X$"]`N.HJ^W6$UD]-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E8R?5M@1LG#Z5C`)W!-D7'B_3MO^XRZIM_P:V/\`"J?[/RU).W^SR_YM
M8MS"(3;,4(_TJ?EK5R'$9MA'W7<0^<@^'B'R=/B'CKIG[R\`36J?N\'Y?DJJ
MF->.E?R*N:D*O6E4O,BJ'Z#S<PM[M5;#**;%+2K*Z5]BO.94X`6+E/WN5T;L
M.B@FJ1=&T[ER#)VQ?MR@S8"CZU5%Y$7_`*Q!^>%_TB?2M[R]00:W%V>+*OCD
MK'D'Z!/T3_@MWM_@MVOT/0W%=N.V$FK"^7?BOG.%?U.!S"1K5W)Y9D"$ECC+
M\$=ROC"]M$5^DA3I2#I>,7,0X(O8Z3.43BF)1"Q<BW=Y,"'E.R.)9\.[^Z>D
MN.UO6B)]H`<#NK(#:XM5PVS;52>3:=P4K#/T-QU24?JV^<E3X$'VU<CQ;XE3
MSVH\Y>%]^B$F-O>5RK72LD43ZT"7B@2$D$!.1"R@`"L=.?$6(%6+^Z,G`@/R
M@&.\HY5C)E;)S'!<MAB5XW_^W*%UJP'BH#=#V9:N>T[(WV?/V3(4"1E5A^Z0
M]"#Y'I8^1-2C>./#V4],;CVFVB5CST)R+NI$8X4?SHKBYR5JKIF1D^GJ*HI+
MQ;9(WR]>P:J\+?XXOB5N&MQZ+[=&;^'U:QO?_)+'Y*DS[2S\5QX]/UB9+=/(
ML66WS@5,/+GB#*J6KAKPWQHU&4E:;BQY[TNH0/=2VG(%K=R]TLTHHBF`)1[9
M6'5=*J#N)6I"D`1$"@-+Q/EL2XN\<PW,Z(YLD6\]$486-`/$D,JCS:Y\ZF;S
ML9:3!V7&%S'$?\IVNS'V7!)]E6Y\JL2Q'VBU#CAB"+>3E2P;'?9U!)QK$[J5
MO>3IIVG(9+MZK-H"IWLU/V7MLB]/5VVL:BD0>V0NV2<6W.7[MFY'N[!,G-;U
M7)-EBA46A0$VLJI=O:SL3UJV[OMZ-DQ[7A@F''&A;#JSGZ;$#Q8V[>"CP%4%
MR%QN:XZ>)5&17;RE\9#UW)O%JI.X2HO1('34"/T.XC-6)CU;R:R1A:M%P!LF
M*AR*J:ONV\A?<E.9&"N`?U9(L[C_`*RWYJ'\P'WF'O&PL*MV3L\6*?08ZLC\
MZW93^C?Q(_.\!V%S5-_LC/\`*U';_!#M^(!'5S^\[^-4OW:+V`-JW$."4<,3
MP]X[QHEZ!98Q@$!+MMMT$5#;;8-MM<D\WD]7ENX2#QR7K<VP)Z>S8R#L(A5V
M>L5J\4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-
M*4TI32E-*4TI32E-*59_SBK0VS!#V'`@J">UU9QT@7J'\W>G/OM]&LNX1D#%
MWT2GI]4X^<5:-[B];!*?X:UAX889=QCQ%\S:$!9N8#%*NR1>-U"C^6BY:.45
M6SENL0>DZ:A3$.4=A#6WY=V29"CGW3[;'Y0000?:*Q),!@UU^D/9^457"%XR
MXZRPD5K!BWQ?D8Q1WKSXSAQC^T+%V'N5]\L*\M67ZQ@W%FJ9TB!OW$0+[)<?
MR.2[GL[:I[Y6W7^F+>K'['``#@?I``^=5R;5C9?2/ZK(MV_,;P-O$$W[=?95
MS".#CY7@8[%G(")>5O+M0:D0QGF%NFFN^FXZ/$%&<8]ED3>[SZ\:*93`0Z@+
M*)E[A!37*H)\6?>_NK(;==@<2[/,;S8YZ!2>[!>Z`]>MK`FQN+6N8P?M<0Q]
MP!7+0>Y)W)`\SX_E/?O5Y%4QDY7M%)RE9T&K')\!49*@VZ2CND[2W11S-E$G
M!CAT*"E\4CTWS85"]Q$JZJ)@\ML2R-R`QY]MQM1VN2998U;O&W7\>EM!MT-@
M:N\>/>1,F6PRE0JQ'YPZ?WQ<>5[5,:N'Z8K!,:V:.($-&Y"+DMDPZ4Q;HV(M
MH<7`#D3Z`*5L$ZZ.H!-O`H[>6J<;IFB9LC5]>T'HD^.C0([7_<"U1_9(/3$5
MOJQ)KM[=6K\IJ3YO&JD#;<E9FAHY.>RA8:Q%TVF%.!"IPL<R;`DU;%76`"MD
M7D\Z.\?J^``@B0H?DB!JJ+<3/B8VSY#>GM<4IDD/BQ)N38=R$`50?$GV6EMC
M:)I<N,:LED"K[.G_`$]2?*K'%L--./D0Y@L>-E[QR6OK1S\>O;1BJ^>TJ.FA
M.>3_`$83%-16.E98RQRE=G`'`@)ECB0O;3UFZ[P_(9Q/N&F#C6.1HB)L)"MM
M.OK9E6W8=.RB_4U9/L2[>A7'&O<I+W<`^Z#WT^1/AX^/:K:Y'B6RIC<'>19'
MM3+D@N&M&KZB$C9ES*_6`O8990'$77&ZHFW,)@=NE!'V4M]S!DT7+9,Y_3VQ
M;P#H97Z(+=+(OTG(_P`4#SJVMLZ0IJR#[Y_-7Z7RDGM^,^RJ6N,'`JNHJE&>
MZIG,(I-TNZJ1$G[%,JBXG55Z0#Q,8=S#X^'EJ\+O1"@.P9O/H/R=*I#MX)U`
M6_'6=WC9$C!8(Q7#B42#'4Z+;"4?#I[8*>&WR;;ZT7R.43[YE3#LTS&LXVY#
M'@Q(?!`*K?N&K+5;7.E*:4II2FE*:4II2FE*>6E*;@'B.E*:4II2F^EP*4TI
M32E-*4WV\]*4TI32E-*4TI32E-*4TI32E-*4TI32E2A=ZJC<8(\*N)"IG=-7
M.YP$2]38XG#P`!\?'57A93860)T[V(^>I<L:RIH;M5+6N#(ML'0HVAWZ`F`3
M(O6@F'Z>VX0*@[2$0']B?8?FU<FWN9CJ!=6\P?RCJ#\U2!B1CPZ>VO>I@6D.
M"=963B-<`(&#W1W[P@!@'J`R8.DA6+TF\0]O<!\AU+&^YZ]&8./:+?DKTX<)
M-[$54V)@W#-BG%R;T)QJW%(S1=\@!GJ8H&`R/>5,90%SHB`="@[*`(>8^>K9
M-*DDADC703W`/3YO;Y=JJ`#:S=:F(YRI%$QO`H>(CMY?2/T!\HZD,P4%FZ*!
MU/D/,U%[/&H*ULL&^5[+61;KGZQ3#MB<R9C@(@)$U>@$E#;AML41UB6V\]X=
MO.4</:]PQYYM>D%"2C->VE9+>FYOT`5B2>U7*?:-RQHO6GA=4M?KW`\R.X_"
M*CG@(?0.LNJVU*+NMG13>DK@,H5W***+24N1'KDW"B@B)CBX,4ZJBVW@!CF-
MT!L!0#8-IZS`LIR-4BIV6]@/P=A\@M>H&7H=%@3X^-4L'`$(Y75</I!59=<Y
ME7"PHBLNLJ?Q,HJJNJ<ZBAA'Q$=Q'5X&_P`Z*%C0!1V'@/FJF.%&Q+,26-=*
M_'^!WZ6P@!0_Z5P8@F-]`)I(%*0/U1-KU=_R/S[?(*'!A\+UQG*WO^/G%C,V
M0H%JT?RN&\(9(O4(S>%.:/>2=(IDW8XY!V0ADCG9K/(\A52@8HB01#<-]2]F
MPDW_`)-B8&0S"+,S88V([@2R*I(]MCT]M4F]YQV;8<O<80"^+B2R*#V)CC9@
M#["16C6OG#U)J!PYQIZO!^>^5)^6N?)26QP_PI+R4XYI!THL]C73.ZK1Y<U"
M7K<DYI[QHM$)0[9-LS51%!7N`/1VB-D^'F?R[(^$YV+%2*#;A,,E0HDZZ!T?
M3ZFL"12',ANP;4+=^2&W7GF)QG'^)8WG(=Y\_P!(X[%C'I]^Q*ZO3(NA!01@
M6(L1X;OJ'+_CK"1L2UR+FO$F/KI]E$-ERRTRR9`KD/-UJG/J^UGGEA?QLI)(
M2#:O,D%Q_.U"`F)2A[0B.VN-#Q7?I'8X&'ESX8R6@218G97D#%0@8`@N?T0;
MUUDO(]F2)3EY6/#D''69D:1%94*AM14D'2/.UJ]>0.9/%#$ZE)1R=R+PUC]?
M)$7'SM%;W#(5:K[BT04L0BD7.Q2$G(-UEH20(H7M.Q*5N<1V`^X"&H<#B?)]
MU]8[;M^9.,=RLICA=@C#NK$*;,/%>_LIF\FX[MIB&X9V+`9P#&'E12X/8J"0
M2#?H>U88_7@Y19_I,APBXS\=LKR>$T.7V3'-;M.9ZP]592+&#+.X]K40RBK)
M'+HO(^*5<7\9!\=DX0<.D&J215BI**`?;OP1XUL.=%O/)M_Q5S#M.,'3'<74
MMIE=B4((+6BT)J4@%B2MP"-7?%_D.]8<FT<=V/(;$.ZY!1LA#8JMXD`#`@@?
M6ZF*D$A0`;$@P/TK;OR]XS<I></%7E[EC*65>/&!J^-ZI7)C-3"SLJHV+".H
M96;.UR);W,DQ:Q<K5[.F\=,#R[Q%@O&+G2,4HK",WXFX?$N1\:V7E'$\3%Q=
M_P`Z7TI,/&*%R6U!;Q1@$LKII#"-2P=0W90(/AYD\FV#?MUXYR7)GR=EPX_4
MCRY]04`$7^M<D`%&U,I<A2A(_.)SFM^5W&5VUQJ]:Y^Q`X:9FD'D3B-RAD&L
M*HY.E(^61@'\=0U"20DM;YG..$V:J3(5CD<G!,0`X@&M,-QKD:-DHV!F!\)0
MV0#$]X05U@R^[[EU]X:K=.O:MM#?]C98&7,QBN42(3ZJ?6D'21'U]\AB![M^
MIMWKIM/+;B]1YB[5VX\@L/5>PXV:1S[($!.9!K$;-TQK+NHIE$JV2*=22;^)
M^*/)UDDV*LF4RZCI(I`,)R[Q8O&.29L$.3B8&9)CY)81,L,C+(5#%@C!;-I"
ML3;L%)/:H<CD&PXDLL.5FXL<T`!D5I4#(&MIU`M=;ZEM?O<>8KHR%R_XL8EO
M4+C+*'(?#F/<A6(K$\/3+CD*L5ZQNTY,0+&*C%2<BW=-D9$Q@!N=8J95MPZ!
M'<->[?Q;DNZX4FY;;M^9/M\5]4B1.R#3W]X`@V\;$V\:@S>2\>VW,3;]QSL6
M#.>VF-Y45S?M[I8'KX>=3GG2FW+)>%,I4/&M^>XOOEUH-GK=+R5&%<G?T6R3
M4.Z90MM8E9.6;L[F"?+IN4^TLF<3)ATF`=AU1[+FX>W[MBY^?`,K!AG1Y(3:
MTJ*P+(;@BS"XZ@]^U56[8N3G[7D8>#,<?,EA=$E7J8V92%<6(-U)OT([=ZTT
ML48U]4?*'J*YS]/9#U6,Z1,Y@VF&NK[)RTO=7D59$$F>.WQHQK6$[4D]CU3$
MR"0HJ'>*E`6IMBCUE`.N]UW+X9[9\/,+GS\7PG@S9?3]'3$"ES,+E_3((^I[
M:0?>'D:Y:VS;^?[AS[-X..1YB28<'J>KJF(;I$;!/5Z$>J.[$>Z>]ZV[:YRV
MXP.LDM^/;;D?AR;SC&$3AW^.FN1*PYNZTY'MBED&!H).34?'FTSI'.LS`#.D
MQ`>H@"`ZY2GXOR./;3OS;?EQ[&WO"4Q.(@I/0ZM.G3Y-V/@:Z:BY'Q]]P^Y5
MSL5]W7H8A*ADN.XT:KW\QW%1'+?+GB]@2:AJWFOD#B'%5AL)$E8:#OE^K=:F
M'S=911%%XG&RD@W>$8*K)&(5P<A4!,40`^X#J#:N,<CWV%\C9L'+RL>,V9HH
MG=0;7M=5(O;P[^RHMSY'L&S3)C[OFXN-/)]%9941CUM<!B#:_2_:L.OK&<C,
MNXKY$>E$RPQF:WT>D9DY#EB\@HT:UJQM<R+35[AA4B#:?58+>XS<`K$3KOH$
MQC(F0='$!Z3[ZVU\)..[3NFP<JDW?$BGS</;M47J)=XI!'DWTW%U;4B].]U%
M:R^)V^;GMV^<:CVO)DBQ,O<`LGIN0LB&3&^E8V9=+-WZ68UF5J/*?C5>JGD"
M]4G.^)[52,3OI&/R9;H&]UR3K5"=1:1W4@2US3604CH1%LW*93NKJ$2%,HF*
M82@(AJ+*XWR#!RL?!S,+*BS,H`PHT3J\H;H-"D7:_;H+^%;1QM_V/,QYLO$S
M,:3%QR1*ZR(5C*]3K8&RV'<DVKQ5SE[Q8N%QI./JGR(PS9KODF#<V6@56!R+
M5I:<N,"T,]*O*UU@QDUUY5F48UR(&2`W65NJ)=P3.(3,CBW)<3$FSLK`S(L/
M&<)*[0R*L;&UE<E0%/4=#YCS%00\BV#)R8L+'S<5\N="\:+*A9U%_>0`W8=#
MU'D?(UQ>^7O%C%^1HK$.1N1&&J/E":%B$;0K3D.KPEH7-*='PLAXF0DD'34\
MGW"^[%6*F+@#!V^K<-,+BW)=RV]]VV_`RY]LCOJE2)V0:>_O!2#:QO;MXU#E
M\DX]@9R[7FYV)%N+VTQ/*BN;]O=)!ZW%O/PK$+R@SUFRM>O)P2P37,KWV$PK
M?L(3E@NF*XVPO6E'M,TU89Y.C)SE?(<&CYXFI7V)@.<HFW:)?M0UM;C>P[)E
M?`[>]]R,:"3>(<Y4CF*@R(I.+T5NX'O-_E&M<;_O.ZX_Q@V;9X,B5-KFPW:2
M(,0CL%RK%E[$W5>X_-'E67BT<P.*U(RA'X3N/(C#57R[**LF[+'$]D.KQ=P4
M=R94S1C)2$>223QJ_DRK$%L@J4BS@#E[93;AOJG%XMR7-VQMZQ-OS)-I6]YE
MA<QV'<Z@MB!8W(Z"QOVK8^1R7CV)N*[1E9V+'NCVM$TJ"0WZ@:2;W/@.Y\.]
M3/F/D5@CCU!,++G7+N/L1P4K(?"8J3R%:8FK-Y22`H**,HP99RV._<()&`ZA
M40.*1!`Q^DH[ZIMGV+>N03MC;'BSY<Z+J98D9RH\VT@V'E?OX54;IO.T;)",
MC>,F#%@9K!I75`3Y#41<^P593SQR/4,V\9+Y4\$>H!B_BY<F)<275QGF+R/$
M@TI=0M]@%>LKR$K!V6-%A&Y09Q;EI&J'=)D?%`PI]PH:R_A6!E;1R2#)WK8L
MG<\1C/&,9H6O(\:^_8,C7,)92XTDIXVK&N59N+NFQS8^U;QCX.0!#(9Q*MD1
MVNEV5UL)@"$.H:NMKBKC6>>,.\;>/&'9_D/R1QRSCAH5%@QS'=[E$PD5E>>;
MU6+]\MT(^EI(ZDZK;3%-)AV5'*@I.`.8P@/4./\`W-NO(=^S,?8-OR#*)Y6^
MSQQLS0+K-HV"K[NCHG4`7%JNXW;;-@V7%FWO.@6/T8U]>1U59FT@%P2;'607
MZ$]#>_C56VV=,+O,8?;8TRMCQSAWX0I/CE1&X0"F/20J*HMUI)2WE?C`IM47
M("D<QEPZ5OJQV/[.K8VT;LFY_<KXN0-WUZ?0]-_5U=[>G;5>W7MVZ]JN2[KM
MC[=][ID0':]&OU@Z^GI_2UWTV\._?IWJ!X5Y,\>N1[*8D,"9IQGE]K7ET6\\
M?'UQA+.>%5=`H+0LJWBW:[F/!X")Q1,J0A50(;H$=AU/WCCV_<?D2+?,/)Q'
MD!*^K&R!@.^DL`#;QMVN+U(VK?MDWU'DV;+Q\I$(#>E(KZ2>U])-KV-K][&W
M:JX^?@/RZL]7:M:/T-^8M_ME/]06_<M^1<].TS$6=X*%B;=FB]==?Q]77SFU
M1Z;!O,3[E)C!QKU^5HB!1.0AU>V4/:$`'HGXT\0V_#R]AP>*;>B9F7A.63'B
M]^5E"&Y5!=B!J/:]KUH[X4\GR\K'WG+Y%FLV)C92J'FD]V-27%M3FR@FP[@7
ML`*SN57E;QHO5ZB<8TG/6);=D2>J#6_0E*K5]K<U9I:F/6B4BTLD?$1T@X=N
MXIQ&+D=%4(4=VI@6V[8]6M'Y7'.0X."^YYF#EQ;?',8FD>)U19`2"A8@`,""
M+>8MWK;6-R#8LS,7;\3,QI<YXA(L:R(SE"+APH))4CJ"/#KVKRS/+SBU7<KL
M\%3_`"&PY"YE?KM6C7&4ID*L,;HH^?%(=A&F@7,DF^1E'Y%2"@U.4KA8#EZ"
M#N&\R'C'),G:COF/@9;[.`29EB<Q@#N=0%M(\3V'B:@DY'Q^'<EV:;-Q4W9K
M6A,J"0D]AH)O<^`M<^`JX<IRF*)@WV#JW#I$!W+N`AT[;[^&K"&!%_"KU7WK
MVE-*4TI32E29D-*17I-D2B@4,^/&J@B1'?NJ%`Q!722Z?:$ZC<#E``\1W\/'
M6H?C[A<DW'X,\DPN(B4\@DVN41+'?U&`L942W4N\(D50.I)`'4UD'%9<.'D>
M'+GV^R"==1/8?HDWZ6#6)OY5:S$7D"Q:<0V1.J]7[:#=NBF87"CD1`B)$B@'
M4!^L0^;;7S&X/\?%CXU%Q';H97WZ9DABA2-C*T_142,*+Z]?:UK$=;6K>FZ<
M7!S#N$[!<=;LS,?="]V+>%K7J\]D#@&C8'0@+@&Z'?$/(5@2*"OZZ@#K[$;4
MN:NV8Z[E8[B((Q+;J/4"+ZECXC7JZUSA.8C.Y@_4ZCI_<W-OQ6KU:KZE4TI3
M2E6E\^/YC7,G_P"+.?O_`$KM6LIX-_YUV?\`YIB_Z]*QCFO_`).W7_EN3_J7
MK2GR=_\`S.<?_IYQ641_"OFS78.V?_T9N'_)5_)C5R_G?^PVWV_G;^_D5>CD
MCBYB7F'ZX6$<'9PC9:;QG,<$,3S]DKT-.RE:4L05C%#B1C8F0EH1RREDHDTG
MV5UB(+)'4%N0O4`;ZQ'`Y)NO$_@QF;SLK(FXIO<Z*[(KZ=<P4L%<%2VFX!(-
MKD]ZRC,X]MW)OBI@[;NH=L#[GA9D5F345BNH8J0;!@#T(Z@5+WK%<3>)7&^T
M<G,IYHS'%9+S)FS"E#Q[PRXYLJ]8G-KP5$8X94ZJ1ETE)Q&UO4%*I&5>F/&W
MODFU;HN%G;D4B.%A5,6/X1<IY9R/'V[;-GQ&Q]GP\R67/RBZ!,EI3([1A?3!
MUL\BG2I:VE>JBUY'Q1X]QG89L_=-WR1/N65BQQX6,%?5CK$(T#D^H1I"QD78
M#4=71FO:\MSPAL'J)>@QQ"9P;QR\Y"X=Q0POV#YI=VHG(/Y:J+S<`I0#29U0
M6;(VNJQB#)JIUE!"19L53&`B0ZQ(<S@X!\<=UDE4#8,O),62MN@60*WJV\=#
MDLP\49P.IK*I.)2\W^$.W1PL?OK%QQ)CM?J634OIW\G4!1X!@A/0&IGX^^H(
M_P";_HT\WJQE11TUY,\=^-.6\<9MC9=([26G%$,=6EG6[\YCER)+-7UB2B'#
M:51$I3(33%T`E(0Z0#(WK@<7"_B_LN3MECQS<-R@FQB""J_6IKB!%P0A(*'Q
MC9>I()J+:.:2<M^%>[P;C==_P=OGBR`>C$^DX60CH06"D,"![ZL;`$"L2&/D
MR?9I]V9'H)_.%S'YE*/ER[IGT:VKN`MN'Q('_<,?^(2?_'YZUOA'_8?A_P#[
M[D?QZ.KTJ[PWP?S1^\#\]Z)GV%F;+2J/0ZGD=G6XFQS-7;2EICJU@N'A7<R\
MK[R/DW;6&+-++HH`L5,SD"&/U%*)38=E\NWGA_P(V+-V)DCS)IWA+LBN0C/D
MLP4."`6T@$V[7M8]:RG'XOM7*?C7O>+O`=\2''CD"*[("XCQE!8J02`&/2_4
MVOTN#B'YDV[C=+Y\]9I+/T=,6CDC-YR1K_%&>,QL<DC7E:=EZ3BKHV=/8QVE
M$Q;4F-8EE'MRR":R1FZ?;1`A@WUM?B.W\AAV#AIV!EBXZN$7SE]P:A)CAHR`
M1J/US,YTD'4;FX)K6G*L[8)-YY9]]!GWXYBKAM[_`+ACR&#BX.D6B55&L$:1
M85O2>FO.3-D]/WAE.6&1>2TU(<;,0J2$E(*G7?/%TZ7$H=YVNJ(JK.!(D`'.
M<1.80W,(B(CKBOXAP08W/-XAQU"0KN.191V'UC=![/*NN."2RS\+VJ6=BTS;
M?!<GN3Z:]_;6!#!\D]A?O"GJ<3,<N=M(Q/%FZ23!P0=CMWK"C<?'35<@_MTE
MTBF#Z0UO/>HDG^`/&X9!>-]SC4CS!ERP?Q5IC:Y6@^.7()X_IIM;L/E$6(1^
M2M9ZGWOC^RXW8,F:VA86G/6(YIIY"LN1$F]G%5;$JD;#NZZ(6$[L\`K+-<A-
M_?.E-,'W<54.H<2'V'HC*V[?9.0YT63Z9X*VS>DD5T_7W8.2MM04Q'2;^Z0`
M`+5HW&S]CCV3$EQS)_31=W]1Y/?OZ(4:3J)TW$@!%O>O?KVMFUE.*T3ZAOJ^
M>KQBF[Q<3;;["X,R(SP%)VZ7G&,-0LBUU7%--QO-&6AU3+(Q\"@\.F*9D'2!
M"N%3B@H8VM,Q\FEX!\*.*;IM[-#@OG1'*6-5+2PN)Y)E][I=R+]P>@&H"ML3
M<=AYK\3.2[;F*)<Q<"08Q=G"QS*88XG]T]E\>A%OS341YU\4KUAK%7H.</\`
MDX^A;I.0F=+[BZ\FJ\_-/(23H]ES!BUM&0,7/+-(&<2:LJ%,MV`&*FW5;E3Z
M$C`!"FU!P;D^'NVY<ZY9QM7@@?`CFBUJH99$QYR6*`NES*I:UV!OU[FO>8\<
MR]LV[AO&>0LD\JYTD,FAFTF-YX`J!K*UA&P6X`(MTM85!N/U'JN)ZQ]YDQ)C
MV)3K6.:#5[C6:A5&CAVXCH2"K\YG>)A8]N9^X=NE4XZ-2*@F=5117M@`&,8?
M'4_?LW*W3)^&^ZY[^IN,\L;R.0`69ABLQ-@![S=386O4O9<3'VS'^(&W8*^G
MA0QR*BW)"A3E``$DGH!XDGVU;YQZPKC+%.4/N\V5*#6$J_?\\7N=F,L6-*0E
MG3JX2,)G.-JD2LZ1>OG#-BG'5N159)I-$VZ/8'8Q3#XCD'(-WW'=MOY]MNX2
MF3!P8$$"64",-BL[6L`3J<:B22;^-639-IV_:\[A.?@1Z,O,GD,S:F)<KD(J
MWN2!93:P`!'>I)S=B*@9GQYZ]')/)4&>T9EPWRXQK#8SN3V2E`<U2+M7(:[4
MR?8LVJ3TC%RU?5:-:L0(X36!!NU2*CV^G?55LNYYVT;AP;CVW.(MHR]JF::,
M*MI&3#BE4DD7!#LS74BY8ZKWJAWG`P]SPN8[]G(9-UQ=TA6%RS7C5LN1"`+V
M(*`+8@V`%K5DLIMAEK=ZL'H36F?>+2$Y8/3?QM*3$@Y547=/Y)UBK.`NWSIP
MJ8RJ[IVL45%#F$1,<PCK7N5CQ8?PLYOB0`+#'R.55`Z``38U@`.P`Z`>5;`Q
M)Y<GXC\.R)C>:38(V8GN28,DDGVD]36)++.)J)DKC!ZN7*6\1"U@SS0>?M3K
MM0R"\E)0).%AK3DJXM+`Q;MTWA&"R<FV63*(K)*'2*U0!$4P3#?9^U;IF[;R
M/BG&,)Q'L4^QR-)$%&EF2%-)[7%K>!`-VO>]:[W#;,+<=DY'R',4R;O#NT82
M0LUU$DLFL`7M8W[$&UA;M69'DOCJH<L/4!]*7&_(2,4R;2+)Z85IR)-UJ;DI
M5%E)7<<37NQC8EC1CYB\^)K3M?8NE#D4**RC)(%.HI>G6H^/9N3Q7@O)]PV%
MOLN9'R185=54D1">%-'O`BP5F`Z=-1MUK9N]X6+R7F7'L+>U^T8K;"961B0&
M<PSL6.D@W+(K&QZE1?H*QSTO%V/X'[MUG/+,16(]ED;(W(NEUJ\VQ,SD\G8X
M+'V7XA"EQ;[NN%&Q&M>1FG0-RI)I[=\V^^^MA9FXY\W]8C#VN:1FV_'P)&B3
M\U&E@.MA[6TK>_E6%8>!AX_P)RMQAC"YV1EQ"1^NIA',F@$D]EU,!:W<^=5X
M]02V8#B.2GHOH<OF4G9^*]<X`XRL&0:<T:STHDM\:J$U'`Y:Q%:<LYE99]-P
M<*5P+8Y5#(-2@81(4Q1LG!,3?9>/<Q;B3+'R>3?IDBD)0?1D4D%G!6P1I+:N
MEV\ZN7-LS9XN0<6CY,"_'$V>%Y$`8_21Q>R$-U9([V/9?&K0<=U[)&1O0VYB
M0N,26:9QUB/GY4\CR%<1.^%1AAXU);A)+J,C]Q8(N.FGT1+/B])B(&;*.U`W
M3.<,JW&?;MN^-6T3[EZ:[EE[$\(;I[V1ZEU%_,J)(UZ]=04=P*QO`ASMP^$.
MZ1[:9'P,;>%D*^\3Z'I@$6ZG2&*.1T`TEC:Q-;'WH]<3."_Z7V#GQP?R;;65
M;RKC>-QO<>.@2$:O6L2V$&5*F)NN3[=VD[N!+-&S\$H\1,[>JH*%D55&PG;*
M)#KGKXL<GYH<2/@O,\>)LG%R#-'E@$/.EY%1U(LFAE8*;*#[@#`.&K>GPSXY
MP\9#\RXA/*,;)@$3XVH%(6M&65@;N'!2]RQ!#$BZE36P/K1M;CK0,XV``^E!
MZ[0"`&`<SXM'80W#_P`VVX^0Z[IY#_[G\)/_`'7(_P!0:XYVC_V[Y<?^]P?Q
M@56/B%@S%^%/43]"R:QE60K$KFSANWRGE%ZC)2KU:VWR>QOF).5G7@R+UT#8
M[EH5-OV&X(M2-T$B%3`">-FY7O&Y;Q\/^;P;E+ZL6'NYAA!51HC6;'TJ+`7M
MU-S<DDDGK5=QG:-OVKFG#LC;X_3ERML]27WF.IVBR-3&Y-K]K#H```*I#QB]
M..S^I?@'G5D&@$J9^8,;SS%Y"96R#:;-"DCJD*,S/VN.2=Q#6:#WJ2EYE-P0
MYV9U2G;)="J8)E`;IR3G^-\.-[V3;\[U?Z)ML=F@B1&N]U2,D,5Z!4T]&\3T
M-ZI]AX+)SS:-VS\7T_Z2+O!(E=W4:+,SCW0P]YGO]'N.XK>.+7,B?8(:H_&V
MX98^R,:Y^D@NEP:?:)^AGPL9WWWL^]>[#9?SCN]ON=/M=/5X:XM$^!]\_:O3
M/W7]JUZ+"_I>IJT6O:^CI:_X:ZN]#.^Z/LVL?>7V;3KN;>KHMJOWMKZ^=5*F
MIIC`,32$@<4VQ54D1,&V_6L;I('M"4/$?IU10PO/)Z<?TJN#,$&H]JE#[4JG
M_G9_UD_\;JL^Z\OP`J7Z\7G4:A[C$SIU0CO>%4FX;N71B$(U;!L)OKG`J=LI
MND-^G?JV^35--C28Y`DL&;L/$_(*C5U?Z/85[F%DAY5XNSC':;\[4H&=*M1!
M5LWZQ,!"'<%^K%0YBCL4HB.P"/EJ"2&6%0THTZNU^YMWZ=[5ZK*Q(4W(J-^R
M</D,`#]`AN'C^N&I7?J*BJ%)5^"0>'D4(:*1?J"(G>I,&J;HPFW`PF<$2!43
M&`?$=]QUBV'P;A>W[V_),#:-LAY#(26RH\6%,AB;ZB9E02$M<ZCJN;F]ZKI-
MSW*;&&%+D3MACLA=BGL]TFW3Y*BVX!X;@'AY?1K*:H:@R-@BEW;F.2>(?$VI
MA(K&J*%1>[[=11(@J)#*$.38Q3%W*(#YZFF&4*)"#Z9\>X^?PJ$,I.GQJ77>
M1JXP<*,WQW31TB.RK=PB5)4@^>XD.H`B40\0$/`0\=5*;?D2+K2Q0^(-0F5%
MZ'O7F'*-3#_*S_\`-3_QNHQM>6?`5")XCXU2[E56IG+O$3DA2Z.S/+6+(W'O
M+M5J<>0Q"JR<Y:,?6&'A6*8F,4@*O)%XFF7<0#J-YAJOXSE0[3RO;\S..B#&
MW#'>0_HJDJ,Q_`H)JT\EPYMSXUGX&*+Y$^%/&@\V>-E4?A)`K\_6:Y+PU_\`
M2VPUZ6E:QQE-[RQ@>7<U:7=4_150B1T)!>[MHZ#1:&7_`$@&T.):Z$:JLSLD
M_=A:*G4.!!+OW5#QR;`^)69\3,G(QEXM)M(02:_(1DM?Z&BT9(8-UN`.M<:R
M[^F7\/L/X>X^-E-R2/="Q318$?6&PN=6LE[:=-^AN>PK8&HD#(UK[QOB"`E$
MNW(5_@-6H*1!,>Z@20BL5NF+M,BY-TE"E<-S``@.PAY:T;EY$65_5[RIXC>.
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M7?'L?8.-<KYOS/C^?%BOR:7KAM*`64F%E+)?]!FC9K`D"QMTJ]9>^<@XWQ'B
MN^;>^0..QFV6(B;$+,#H8`@'6HD47Z7!%Q>I+X]6M7EOR1]<3DSQHH-Q8\<L
MI\)<ZLD"/8!1B>>R).UNL/8EO[BR5>,@MT_)P,_+^Z)*K.$T7)Q.`&6`!K=]
MQEXGQ_A7'.1SPGD&+O>*20X(6%7<$W-CZ:*T4=[`7`\!5#L^1)R7?>8;]L<,
MR[#D;1DJ`5L6F9$M[HO=W*R.!U(!MXU:MQYSO6,FK>@GBBNUZ])27';DU:H&
M\6N7K+AA1).>OO)&EW2/AJ=9155;V)_#UQ=LO)E(5,68NT2F`>K?64\@V;)V
MY>=;ID/`8MPVV-HT5P956/#DC9I$M=`7N$/YP!/2U8[LN[P;@_"]M@CG$N%N
M$BR,R6C+29<;@(U[,56Q8="NH>=9Y.&(&+]XM]2Q3I/TFP37"D-T&`AS%9\=
MAZ2'$.DP^R/E]/S:T?S$AOZOW'`I!OFM^7+K<7%@?_7'D!\/L4?^;B5B3RKR
M>NOIS\M?60K*4+;*KR9Y%90J%@XJRZ>-XFZQ<BRELOS=P>32"%ECY.->,YK'
M]N,DU%)F\!9Z!T``BZ0=.U-MXYA_$/BG$,@O#+QK;L61,Y?6:-@5@6,(2A!&
MB:.[#4I"^]U4UKC/Y!F<%Y+RG'594Y!N&3&V&1&K@AIW<GWP5L8Y.GNMU!'1
MATW/N(*^6W?%GCV]SV0R6:G^(*#(9114BF$$LVN\A7(][/M7,)%-&$9$/&K]
M<Z:[9!%))%8IB%*4`VUR#RE=I7DN>FP]=F&7*(3<M>,.0A#,2S`CJ"221UO7
M4?'&W)]@PGW@6W5L6,S"P4B0H"X*J`H(:]P``#T`K7,P+!O;']X=]2ROL2@5
MY8.,5MA&)U=TT!>2E*X],6_4L8`(4H++!N._@`#\VN@]]G3&^`''9W/N1[DC
M'SL),L]JT7L^.^5\=-_@3_2;8RW\+M'B#K\]8E>(_,+D-QTP!BST]N-\%<*=
MS>=<Z+&CD>ORF(*Q9SCCF7A*[6C0RBUP@YQ2-<,K/'*.'9RMT`:,FAG!EP1-
MN.S^6<2X_P`BWS)Y]R*2&;A2[(IB<3NGUJLSZK1LM[QD!>K79@NG5VU]QKE6
M][+M$'"MDCEAY:V\-ZJ&%'^K**NDEE>UG'O&PTA;D@7JXWD)R$G_`$V/5,]4
M^_VIO?:1<^0V!+XQXMW>OUEO+-'=\OJN-[%1;"V7E2*1"\/&R,$\0=+=IX1N
M[:&241$1VUC^P;#C_$7X9\8P,4P3X>W[A&<V)G*D11>JDB'2=6I@RD+=25:^
MH"KUON]3<$^(7(<[($T65G;?(,.15#`RR>D\;=>FE2"";&S*1:XJHW)JR<A[
MM0_N\-UY32%CF,Y6[D;-VJWO[1#M(6?4C)[..)).E'EXB-C(AI%+_H,XCA[/
MNR)R$V[@=SK'5OXS!Q_#S?B#B<9$:;+%MRQQJC%ENN-D+)I9F8D>J'ZZC?SM
M:JWD$V^96'P?)Y$SON\FY,[E@%;2V3CF/4``!]65\!T]MZ[J"4PSWWI$0(?Z
MQIDH4_JS_6!^EN>?%/P]L/$/+?SU[G$>A\,B2.C0_P"9BFO<,,9OB)T/59?\
M[+JD6/BG!_\`=BOJU?J[1<Q4^K/['_N3K^W7[/L[[#MOJ[Y[+H^)%K7,,?\`
M$WJW82,7X#[)I?XW'5O')G)"?'$WK2\*<BTN_H9IY8<H\97'";&.K#EW&V:O
M0>=;5D0LD18#E=+(3U8GV:D8+5)S[XLL*0=)R&#5]XU@'D`X=S+`FQSL^U[9
M-'DEGL4=\6.'3U%KHZL'N1I`OU!K']_RCLAY5Q+.BF&Z[GN,,F.`I(=1E22W
M\_>1AIL#<].E90HRBV'&/J]>A_CJV1[F,L]"]/6@U*T1SA(2*Q5AAL89S92\
M8YV`2$<1\B0Z!@$?RB_3K6\F?C[E\)N:;ABL&QLCD$LB,.S(TV*58?*"#^&M
MB18.1M_Q-XA@Y2E<F#8TC<>3+!DAA^`W'X*Q`YUO;C#6.?5`]/\`N=#R$3D7
MGCG/2[SC.O1U8=OF=A@(?(-FEBN6BI!!XZ^/1[QBK%>[(+ED"/B"00`I]MI[
M'AIO&?QKGF'/C_T?PMEDCF8N`49HD6Q\/=.H/<C3I-ZUONN;]U8N_<,RH9_O
MS,W2)H55+AE661M0_.LPL4L"6#`BLC/JZGQG0,P^FOC+.5AS5Q4F\8\-XNO7
M/EABN#F+5(-_>:R%14Q-!P$3,UH9#X1,14B:7=MI$[A!E-`D+55)83!K[X4M
MN.X[5R3<]ECP]T@R=X9H\&9E0=&$GKLS*]M09/3!4*6B)U`BLU^)/W?A;IL.
MV;N^9MT^/MBJ^9"K.?H%#"NED)TE6UE6/NRV*D&I\Y73/"A'[O==<7\&\J'R
MS0L7Y'Q(QMTM+L7L/D`]ZL^4HZQS,M=JO(1D0_A'$ZX74.R*5O[I[HB5)!10
M$#F"AXI#S(_'N+<^:XOV7.R8)S&JD-%Z:0E%$;J65M(`U6-[F[`%JN'(I>*_
M^BLN!Q'(.1A030ABP99-;3JS&16`9=1OIZ:;"RDV-0_EW>8KBSR@]$#FAE^J
M6=_QTH_"O'].M5A@:X-C(VL9,8SR9H55FJ9%D,EV+XQ=(H*JIJ+I)+F2`QD3
M`$[BV))R;C?-.';3+$.03;S+(B,^BZ^NOO7ZFP,3`D`@'2&MJ%4W)LF/CW(>
M)\MW))#L<6UQ([*NJS")^A[`'ZU2+D$@,1]$U4C!'J<\[<<^FYD+FMEK"K3D
M-3+=RJ7H\9'6&FQ-!85WC:^J1FSVY+1%$J3!O9:V%O'X*9X^(HV564,4ZXI!
MOJU;Y\-N#[A\1H.&[5EG;\R+:Q(S+(TI?+#W$8:60Z'T?66%C87`!JZ;1\0.
M787`YN6[IAG-QI,\HH*)&%Q3'<R:44!DU_5W:YN;$FJ(^D7EBF8_YL>ICR<X
MJ4C(T?Z>]1P+=\F_HDZC589LI.UH(2Z5FG1#=ZZ<13*PM10LZ,2V,Y449Q"I
M2JF*02@-]^*VUY>;PWC?&>3S8YY_-GQ0^IJU'0^N-Y&(%RI^I,A`]YU)`)JR
M?#3<,;#Y9R#?^.PS+P:+#DET6T_6+HD"*"2`;>L(Q?HG0UM`\">:=1Y]<>(3
MD52*99:'7YRQVVMH5VW.8IU-H.*E*C%.G"ZL,X=,>RZ5#J3`#B8"_E;#KF[G
M'$,O@W(7X]FRQ3SI&CZX]04AUU`>\`>@KH'B7)\7E^R)OF'&\6.[LH5[7NAL
M>UQUK3@XUD4__*+UV"BFJ!C9GQ9TAVS]1O\`Q;;_`))>G<WA\VNN>1,O_J?P
MGJ/^R3_Q>N8-I5A\.^6].^5!_&!5WN%RF#G_`/=VQZ#])/3XKY3FZ#`4AOLX
MS$7I.(AL0P&\-AV'?6*;PR_T%^(%B/\`\\W^N@K(=J!'+>#?\G3\<,]6$TSE
MIR$X%X_YE<*\/&RQC3G1?N>$=,TA"LT=A-J3E'51EX5^U8ISL;,).C659-@M
M'BBS5!XU=)K)*@0#CK-,WB^Q<ZS=HYCNWV:?A,&QE9"\A71)=6!;25MH!8-=
MAI92"+VK&,;DV[\.QMSXIMPR8>6S;P&0*@;5&0P-K@WU64K8'4""O2MU>G9@
MOMOC\U\?&S"599_PKQVQ!-RES<N(D\7.9*S!0KW\-4BTTR"BBXA;70UCN153
M!N87"?0'0!@#CO*VK!Q&P]\9E.QYF?D*L8U:EB@DBU:OW22@+8WZ&Y[5U'C;
MEFY(RMD4$;UBX,#&0Z=+2SI*`0/\%XB2"+=1;I4S<RK2-.PJ[FBJ]H26:M-N
MOJZ=O>7BA-M_IU!P[&&7O0A/;TG/S"KIN\WH81?_``@/QUBF8<A6*+@JLDLN
M^;IAU`R0=BS!T<!\$W#H"J+(-_#VNV7N"'@4Q1]H-IR[!(5TQV4^9%[?(.ES
M\O0>VL93<D!NUR/R_A\/[]5*K6=<@9DLD+CRK*H()O#G]U@HD@QE>AHYL7NO
MY>4Z#F.+*.;`*B[ETHJH;;;J$Q@`;9D['MVRXLFXY5V([LWO.['H%%_$GH`M
MK#Y*J8MPR,V5<>*POX#H`!W/R#^ZYJY9OR$@6UAJ_';`$FE9K-+R98NR9%(4
M'#(CH"F4L$G$"'6D\&/9H*G]X]INB1,")=PWMABK<>R'@EY'R!?2Q434D/8D
M#HBGRU$CIW/4GI5R^\8Q(NW81U2$V9_+S(^07]@Z5<A!9UJCF=RO$0[])Q4,
M#U5L:USYW'?*XGTTI)R^9INC&-WQBV,,<BQ]]U'1S%\>C<<<FV3,7'Q)I`5S
M,^0^FG^![H4].VHL"/)1[:N*YT1DE0&\<*`L?;UZ?@MU]M3BMF.OM8_#DJ],
M1LUS"]B(N%ZEPV0D)RK.[''(F-L!5!64;E;!Y?6*EU2C:LAI<R./WCA*S-[0
MKA"?D`.KY!4PY<86%CT$Q`'X5N*DB=R:]L$YE;&%=D2166\=MV=OJ;3JZD['
M!.8YM)L1!JH(D>(+'7/'.TMMBF434#;?<M9!MT<$&)NN0"^T9!*2&_T&!93U
M\#V9?D(\*E-DL\DN+'TRXQJ`/B#U'_0?+I5L`YGKW)JL**TQ9*N9ZJ+-9V>F
M*.?=U;>Q8E,=^UKRJIDSNWK8Q3'11$0<MU`%,VZ9NX&3C9I^,9>G.'J[#,;>
MIW],GL7'@#XGL1UZ'H;9]NCW..T!TYJ==/F/$`^)'XC5L)^6LD]:?!KCTV)N
MT$[9%9^<["T0JJ9Q(JDTF`3%R`I*%Z3MWB:Z6X;"4!\0RD<2BC?U\`^DYZD+
MU1K]>J]NO@1;SO5K^]R1Z<WO6Z=>C#\/@?P5)*V?R=TX-Y)4Z`&'M&6,0BPI
M_L>Z1,ZA`4^0>D1#?RU<%V$D#6H#?W>P5*;<0#[IZ5FIX_2I;'A/&TP<06+)
MU6.="(^T!NOK$#;COOXA^+6E]^@$&\Y4-OHS$5F&`_J8<<GFHJ?DZ33$;"K;
M4:E64K6L04UK.E`Q:=B53,EV3$5FR-0DU"F1]@0%40$OAY:H#E938XQ&DD.*
M#T34='G]&]OQ5,&+C"?[4(XQDD6UZ1J_RK7_`!U&BQL<5T#XK!F#TI.V5X#9
M'WH""`AT`XZ.\!-AVVZMMM2=3!=%SI\O"INA`VH`:O.W6O(M7H!P_/*N(2)7
ME%&!HM226CFBL@>+.KWSQIWJB)G)H\ZWMBB)NT)O'IWU$))!'Z09A%JU6!(&
MH>-NU_;WKSTX]6O2NLBU["]O*_E[.U'5>@'T:XAGL)$O(9VB+=W$.H]HXBG+
M<QNLR#B.52.S61,?VA*8@E$WCMOHDLD<HGC9EF!N&!((/F".M_;7C11/&865
M3$18J0+6\K=JZH.K5FLQQ(>M5Z#KT2DHHLG%P44QB(Y-9;;O*D91Z#=L5178
M.HP%W-MXZ]GFFRI/6R7:2:UM3$L;>5S<UY#!#CH(X$1(QX*`!\P%JY9UBMQ[
M9LSCZ_",6C)99PS:LXIBU;-'#E7ON%VJ""":3==PM[9SD`#'-XB(CH\TTC%Y
M'9F8`$DDD@=!?SL.U^U>B&)5"JJA1V%A8?)7O3CH]%PH\18LTG:H`"KI-LB1
MRJ`=.P*+E("J@!T!X"(^0?-J$LQ4(2=(["_2H@B!M0`U>=NM>-Y7*](OV$K(
M04._E(HXGBY)[&LG3^-.8W68T>\714<,C"?VMTC%\?'SU$DTT:-$CLL;_2`)
M`/RCQ_#4+11.P=E4NO8D"X^0^%1@I0*&Q0V#Y@U*``%AVJ97B",C0<J/"Q[(
MKQ8.E5V5J@5TJ4>G<JC@I`5.4>@/`1'R#YM1%F*Z"3I'AX5#H0-K`&OSMU^>
MO(6N5XDNK8204.2?7;@U7G"QC(LPLU*4I`;*R@(@^40`A0#H%02[``;:C]67
MT1CZV^S@W"W.D'S`[7J'THO4]72OJD6O87M\O>OF2K5<F3,CS$##2QXU?WJ.
M/*1C*0/'N?`?>&1GB*QFB^X![:?2;P\](YI80PA=D#BS6)%QY&W<>PUZ\4<E
MO456T]K@&WR7KW+QL>Z.FHY8M'*B1NM([ANDL=(XB`B9(RI#&3,(E`=R[#N`
M:@5F0$(2`?*O2BL;L`2/.NL(>)*+D2Q<>`O/!X(,FP"[#VA_.A[>[CQ,(^WU
M>(Z]UOTZGIVZ]ODKSTX[DZ1=N_0=?E\^]<!#Q`"V$(N.`61NIF/N3;=H;J`_
M4U'M?FX]8;[DV\?'STUN;W)Z]^O?Y?.ACC-B56Z]N@Z?)Y5YW=;KK^28S3Z!
MAGLQ%@)8R6=QC)S)QQ1,8XE8/UD#NV9>HPCLF<OB.HUFF2)H4=A"_P!)02%;
MY1V/X:\:*)G$C*ID'8D"X^0^%>LT7&G73='8,U'211(DZ4;)*.4BCU;E3<'(
M98A?;'P`P>8_/J6&8+H!.CR\*B*(S:B`6\[5XUZU7'4JTG7,!"N9N/2[+"97
MBV2TLQ1'J^J9R2B!GC9/VS>R0Y0\1^?4:S3)$8$=A`W=02%/RCL:\,49<2%0
M9!V-NH^0]ZUU_42XV>H>R]0W&W,?!.#J!S3PO2,9J4VK\?\`(=I@HZ%QS9IA
M@_C;98F59M4G$Q83<RHJDZ1FF8/'/1U-EB%(DD.M]_#_`'_X?MP/)XCO69/L
MV\3Y'J/E1([&5%*E$+QJQTK:QC;2+^\I)+5I;FVR\V7F6/R79\2#==JB@T#'
MD=0(V((9U5V50Q[ZQJ-O=865:K%Z/W`C/&`+KRXY(\H*-C7$URY86R"F(_CO
MC$T8^HV-("#DK+,IHG1B5G];;NE7ME%)JU:N'0MD&YCJ*`HN9-.U?%?F^Q;]
MB;5QSCDV1EX6U0NIRY@PDF9P@/TK.1[ER2%#$V`LHO7_``TX=N^S96Y;[O\`
M#CXV7N4JL,:'28XE4LPOI++>[V`#-8"Y-VL,Y,C7H"7CS1,M"1,K%'[77&24
M<T?1QNP(&0ZF3I%5L((F#<GL^R/EMK3$<LL,GJPLRR_I`D'YQUK;3QQR)Z<B
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MNPR:ZI$SK+'21Z$Q.;H`=7OF/)9^7\ER^0SIZ?VB2ZI>^B-5"1I>POI0`$@`
M$W-A>K5Q;C^/Q?8<;8\<AE@0ZFM;4[,6=K$D]6)(!)(%A<VJYLL)#$371)$1
MA$71BF<HE8-2I.3%'J*9PF5("+&*;Q`3`.PZQO6]PUSJ';KV^2KYZ<=BNE=)
M[]!U^6OHL/$D.@H2+CRJ-2=IJH5DW*=JGL)>VV."8&03V,/@38/$=-3&XN;-
MWZGK\OG7NA+@V%QVZ=J\YZW7E)9O/*04.I.M4!;-9M2-9GF&S8Q3E%NWDSHB
M^11$IS!TE4`NPB&VO1+*L)QU9A`3<K<Z;^=NUZ\,41<2E5]0=C87^?O43(V;
M)G45(@B158I"+*%3(514B?4"95#@`&4*F!QZ0$1VW';SU!X:?S?*HK"^KQ-8
MU_5EL(UCB'*RH*]KIR'CY#JW$/W>65+MN'CX[:V-\+(/M/+%CM?_`&>4_,M8
MQR^;T-G,E[?6I^6M87[9C!O^>CY^?=WV^CQ$!#72QVI#W!K5OWC[?Q5/L?RH
MF8"G2E.K#T().T@4MWFV[@?CMF8HJ"=G6S/B[*QU3;&^M49HB'OK@>MP8Y2)
M)IVZ3B^/D9J9F4/4]+]4I^BA/=[>+GL&-](Z*`22:I-Z,<!AA.G5](CNP_1]
MB^-AW/<VZ57S$W(Y'C]A^S96;ODRY;RXC)X]P\B8Q1<52D,%NQD3*(E$!,@H
MZE"IPT.;P%1TW=G#<B!P&P;MQ\<AWB/:BI^ZL,B7(/Z<A_50?Y-Y)!X*4[$U
M<,7=1MV$V86'VN:Z1CR7\^3\)`5?:&\JF^MY_#''I_W1X$D);%R+SJO26)U%
M#&<K4_',!!S%L?"L8XJ'35DI1-F<WCU"[-N([CJER=C&X\^ACT_[/MV")#;L
M))794%OW*W'[FIL6Z+C<>>0M]9DY&@?N44%C?Y3:_F:JORAY'NVO#/T\Y^(E
MO=9MTQLDTW=IJ""B$EC(T75VCCV1`1%"0`1\]_9U:>,<?C?F/(,>9;PAD4CS
M$VIR/PK5;NN[E=EVV5&LY!(/MCLM_GKS<KN7CUO>N*O,G%;WX2ZR!C111VW5
M.46Q+CCJR/8&\526214,"S%5.5(U53$0,=J<APV$2B$7%.*1-@;KP_=5U#'R
M>A\=$J!HW4D="-)8>VX\Q4.[[VRSXF\XAL)8O_J0Z74CRZV^3K5M/([,$(E?
M*YGC$4F[A*;F%%2^U\C!Z=K)X_R)&NTT,BTE9TU[)FDM6[.J#Q`Q.D%(^2;*
MD]@X:R3CFUR-@2;#NZ!\S#/I-<7$L1%XI0#>ZN@TF_YR,#UJV;GN""9-PQ&*
MX\XUBQ^BX/OIT[$,=7R,*H_D'E!]HL@A:I9-NSO#PG;M\G&`DSB[<[3(4J5I
M<1Z()HQMF>D#ID>R4&[Q4`<`5-0ZH&O&W\;^[E^RPDG`!^K!ZF,=?JP3U*"_
MN7ZJ/=^B!:CR=Y&2WK/89!^D1V;R:W@WZ7@>A[U3W[9C_P"??@!7^^WU<ONI
M#TL:I?O*WC6W[P8D_C/$+CU*=77[]C.!<=6^_5UD5]K?Y=]M<E\UB$/+-PC'
MADL*W%L+^IL^,_G$#5UVL7J[TTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5AA]>BPEK'I_3LH93M@3+F)D
M.K?;;OSRY/Q[:W!\#L<Y//$B`NWV2<_,M:Y^*>:FW\4;)<A5&1$+GVM6DQ]L
MJ/\`GI?^T#\6NRON>3OH_%7-G]*H;_K5^<4',B1O\M#YO!0/Q:\^YY!^9^*O
M!RJ#MZJ_.*BDMGYW-KM%I&5[WP^+CH2.2*?MMV$1%(=AC'M$MS`@W2W,<0#\
MM90ZAMSG,(RHM@]!2L4=@S%CYEF-R3YGP^0`=JF2\NAE(O*ILH``(L`.P`OT
MM^6YJH%\Y0HS]+PU0V,A_P!R8QITVD)`4$"K6V]V^8M]K?"`CL90J#F/8=6W
MB2/+JWX'&)(,W,SI%^NR9E_`D4:QH/\`/8?N_.]5F;S/%EQ\;%24:(8C?J/I
MNS.WS`JI_<_)51,K<J6MGXY\1Z.64!1QC:.SVU>(]THBW_27*:<PPW*&YB@=
MD`;;[>7AX:MVU<6EQN1;MG:/=R'QB/;HA*GYCWJLW#F>-+LNWPB5-40G!ZB_
M62XO^3\%2*?E(WE,#(8LDY(#+TS*J]^I9CJ";M1UWK)(&_Q27[1-22J\(]*7
MR$W>-YCXUPXM)#OWWI$ATS8OI2=/SHWUQ-\SRK\U4O\`33%?:3A22J)(\CU$
MZ^#KID`_"J-\FJU4Y)R">D@7-8^*`I"N99K/`S44$Y&DPV:K1XR#+VMF[AW'
MK=A?8-EDR)]6XI)B6Y'CX.0,HH?5"%;^:DWL?,`]1Y$FW<WHAR^(1&#U5*$W
M[CH1XCKY=#Y]+]A4'^V5';]^%#]17?4\[/(#]#\52SRJ`?Z5?Q5]?;*EOO[\
M&_S=?^]MKS[GDM]#\5>?TJ@'3U5^<5^@IZ8<G\9]/SB3*`8#@^PO5G`'`=^K
MK37\=_EUP9\2(O1YYNT1Z%<QQ^.NLN%9"Y?$\#)0W5\935]^L)K**:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*E*Y_P`#G_U2_?#7_7/?X-^Z&_+^3WG_`*K_`(V^JG$_7C];V/ZOZ7_R
M\_95+E_JO]%W_P!)]&J3CY_T>OP^>KL?^/JU^'\`KZ_^OFG_`.PKSP_@%?(_
M[/7E\OZO]S7G[?7H_P"`KD?/^CWY?+Y_\&O#V_A]#_P%<?L?Z/7F/_)_*'\?
MS_3IX_P^G@/^P>/]W_37(^7]'O\`#Y:]\?X?0?\``5R/^SY^'7O[?0_\!7R/
ME_1Z_#Y:#_CZ\'?^`5S\H?S>_P#=_!I^WUZ.W\`JM5<_@2-_@7][$_U<_@3Y
M?X-_T;YM66;]:WTN_P"=]+\/MJ\8_P"I7Z';\SZ/X/94:U*J=32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
$I7__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
